Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

Also called NCT03001076

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 269 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03001076
Other papers using this trial's data
  • Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study Atherosclerosis, 2018-10 DOI, PubMed 29910030

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03001076. Randomized; triple masking; primary purpose treatment. Start 2016-11-29 (actual); primary completion 2018-01-11 (actual). Results posted on 2020-04-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Condition
Hypercholesterolemia
Condition
Atherosclerosis
Condition
Statin Adverse Reaction
Intervention (Drug)
Bempedoic acid
Intervention (Drug)
Ezetimibe
Intervention (Other)
Placebo
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03001076
Content hash
eed13b5d98f487035995e272c44918413aedc1ba430ee884bbd4f114377b88d4